APA (7th ed.) Citation

Dickinson, G. L., Lennard, M. S., Tucker, G. T., & Rostami‐Hodjegan, A. (2007). The use of mechanistic DM‐PK‐PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example. British journal of clinical pharmacology, 64(1), 14-26. https://doi.org/10.1111/j.1365-2125.2007.02850.x

Chicago Style (17th ed.) Citation

Dickinson, Gemma L., Martin S. Lennard, Geoffrey T. Tucker, and Amin Rostami‐Hodjegan. "The Use of Mechanistic DM‐PK‐PD Modelling to Assess the Power of Pharmacogenetic Studies –CYP2C9 and Warfarin as an Example." British Journal of Clinical Pharmacology 64, no. 1 (2007): 14-26. https://doi.org/10.1111/j.1365-2125.2007.02850.x.

MLA (9th ed.) Citation

Dickinson, Gemma L., et al. "The Use of Mechanistic DM‐PK‐PD Modelling to Assess the Power of Pharmacogenetic Studies –CYP2C9 and Warfarin as an Example." British Journal of Clinical Pharmacology, vol. 64, no. 1, 2007, pp. 14-26, https://doi.org/10.1111/j.1365-2125.2007.02850.x.